Changes in Haemodynamics and Body Fluid Volume Due to Enalapril in Patients with Essential Hypertension on Chronic Diuretic Therapy

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1986 Jan 1

PMID 3028815

Citations 1

Authors

B A van Schaik

G G GEYSKES

P Boer

E J Dorhout Mees

Affiliations

Soon will be listed here.

Abstract

In 12 patients with essential hypertension who remained hypertensive despite chronic chlorthalidone treatment, the effect of 2 weeks of additional therapy with the converting enzyme inhibitor (CEI) enalapril on blood pressure and body fluid volumes has been evaluated. The objective was to examine the influence of a diuretic-stimulated renin-angiotensin-aldosterone system (RAAS) on haemodynamics and body fluid volume. Mean arterial pressure (MAP -21%), total peripheral resistance index (TPRI -22%) and plasma aldosterone concentration (PAC -39%) were decreased, and plasma renin activity (PRA 660%) was increased. The average heart rate (HR), cardiac index (CI), plasma volume (PV), blood volume (BV), extracellular fluid volume (ECFV) and body weight (BW) remained unchanged. A negative correlation was found between the per cent changes in ECFV and PAC. Thus, body fluid volumes during chronic diuretic treatment are well preserved even when the RAAS with its sodium retaining properties is suppressed by CEI. Possible mechanisms are a volume (not angiotensin II) - dependent stimulation of aldosterone and a fall in blood pressure.

Citing Articles

Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Todd P, Goa K Drugs. 1992; 43(3):346-81.

PMID: 1374319 DOI: 10.2165/00003495-199243030-00005.

References

Boer P, Hene R, Koomans H, Nieuwenhuis M, GEYSKES G, Mees E . Blood and extracellular fluid volume in patients with Bartter's syndrome. Arch Intern Med. 1983; 143(10):1902-5. View

Bauer J, Jones L . Comparative studies: enalapril versus hydrochlorothiazide as first-step therapy for the treatment of primary hypertension. Am J Kidney Dis. 1984; 4(1):55-62. DOI: 10.1016/s0272-6386(84)80027-x. View

Shoback D, Williams G, Swartz S, Davies R, Hollenberg N . Time course and effect of sodium intake on vascular and hormonal responses to enalapril (MK 421) in normal subjects. J Cardiovasc Pharmacol. 1983; 5(6):1010-8. DOI: 10.1097/00005344-198311000-00015. View

Fouad F, TARAZI R, Bravo E, Textor S . Hemodynamic and antihypertensive effects of the new oral angiotensin-converting-enzyme inhibitor MK-421 (enalapril). Hypertension. 1984; 6(2 Pt 1):167-74. View

Hodsman G, Zabludowski J, Zoccali C, Fraser R, Morton J, Murray G . Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man. Br J Clin Pharmacol. 1984; 17(3):233-41. PMC: 1463367. DOI: 10.1111/j.1365-2125.1984.tb02337.x. View

Roos J, Boer P, Koomans H, GEYSKES G, Dorhout Mees E . Haemodynamic and hormonal changes during acute and chronic diuretic treatment in essential hypertension. Eur J Clin Pharmacol. 1981; 19(2):107-12. DOI: 10.1007/BF00568396. View

Hollenberg N, Meggs L, Williams G, Katz J, Garnic J, Harrington D . Sodium intake and renal responses to captopril in normal man and in essential hypertension. Kidney Int. 1981; 20(2):240-5. DOI: 10.1038/ki.1981.126. View

Jackson B, Cubela R, Johnston C . Effect of dietary sodium on angiotensin-converting enzyme (ACE) inhibition and the acute hypotensive effect of enalapril (MK-421) in essential hypertension. J Hypertens. 1984; 2(4):371-7. View

Griffing G, Sindler B, Aurecchia S, MELBY J . Reversal of diuretic-induced secondary hyperaldosteronism and hypokalemia by enalapril (MK-421): a new angiotensin-converting enzyme inhibitor. Metabolism. 1983; 32(7):711-6. DOI: 10.1016/0026-0495(83)90129-4. View

10.

Richer C, Doussau M, Giudicelli J . Effects of captopril and enalapril on regional vascular resistance and reactivity in spontaneously hypertensive rats. Hypertension. 1983; 5(3):312-20. DOI: 10.1161/01.hyp.5.3.312. View

11.

van Schaik B, GEYSKES G, Kettner N, Boer P, Mees E . Comparison of enalapril and propranolol in essential hypertension. Eur J Clin Pharmacol. 1986; 29(5):511-6. DOI: 10.1007/BF00635885. View

12.

Gavras H, Biollaz J, Waeber B, Brunner H, Gavras I, Davies R . Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421". Lancet. 1981; 2(8246):543-7. DOI: 10.1016/s0140-6736(81)90937-5. View

13.

Roos J, GEYSKES G, Boer P, Dorhout Mees E . Systemic hemodynamic and hormonal responses during angiotensin II blockade with saralasin. J Cardiovasc Pharmacol. 1981; 3(5):1106-15. View

14.

Hall J, GUYTON A, Trippodo N, Lohmeier T, McCaa R, Cowley Jr A . Intrarenal control of electrolyte excretion by angiotensin II. Am J Physiol. 1977; 232(6):F538-44. DOI: 10.1152/ajprenal.1977.232.6.F538. View

15.

Bauer J, Gaddy P . Effects of enalapril alone, and in combination with hydrochlorothiazide, on renin-angiotensin-aldosterone, renal function, salt and water excretion, and body fluid composition. Am J Kidney Dis. 1985; 6(4):222-32. DOI: 10.1016/s0272-6386(85)80177-3. View

16.

Ajayi A, Campbell B, Howie C, Reid J . Acute and chronic effects of the converting enzyme inhibitors enalapril and lisinopril on reflex control of heart rate in normotensive man. J Hypertens. 1985; 3(1):47-53. DOI: 10.1097/00004872-198502000-00008. View

17.

Brunner H, Gavras H, Waeber B, KERSHAW G, Turini G, Vukovich R . Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med. 1979; 90(1):19-23. DOI: 10.7326/0003-4819-90-1-19. View

18.

Fujita T, Ando K, Noda H, Sato Y, Yamashita N, Yamashita K . Hemodynamic and endocrine changes associated with captopril in diuretic-resistant hypertensive patients. Am J Med. 1982; 73(3):341-7. View

19.

Hochberg H, Salomon H . Accuracy of an automated ultrasound blood pressure monitor. Curr Ther Res Clin Exp. 1971; 13(2):129-38. View

20.

van Schaik B, GEYSKES G, Roos J, Mees E . Changes in blood pressure and body fluid volumes during diuretic therapy in patients with essential hypertension who receive enalapril. Clin Pharmacol Ther. 1986; 39(1):60-4. DOI: 10.1038/clpt.1986.11. View